Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 21, 2019
Theravance Biopharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference
DUBLIN, Feb. 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that management will participate in a fireside chat at the 8th Annual SVB Leerink ...
February 21, 2019
iCAD to Showcase ProFound AI™ Solution for Digital Breast Tomosynthesis at ECR 2019
NASHUA, N.H., Feb. 21, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc.(ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it ...
February 21, 2019
Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH
Daix (France) February 21st, 2019 - Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas ...
February 21, 2019
Celyad Announces February and March 2019 Investor Conference Schedule
MONT-SAINT-GUIBERT, Belgium, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
February 21, 2019
TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019
SAN DIEGO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
February 21, 2019
HTG Molecular Diagnostics to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on Thursday, March 7
TUCSON, Ariz., Feb. 21, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today ...
February 21, 2019
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
SANTA MONICA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today ...
February 21, 2019
Celyad Announces February and March 2019 Investor Conference Schedule
MONT-SAINT-GUIBERT, Belgium, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
February 20, 2019
AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease
LAUSANNE, Switzerland, Feb. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, ...
February 20, 2019
Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions
HAIFA, Israel, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today ...
February 20, 2019
AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
February 20, 2019
BrainsWay Expands its Deep TMS Commercial Footprint into Asia Pacific
JERUSALEM, Feb. 20, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (BRIN.TA), a global leader in the advanced non-invasive treatment of brain disorders, today announced that the ...
February 20, 2019
miRagen Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results and Host a Conference Call on March 13th
BOULDER, Colo., Feb. 20, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
February 20, 2019
Zogenix to Present at the 8th Annual SVB Leerink Global Healthcare Conference
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, ...
February 20, 2019
VBL Therapeutics Awarded $2.9 Million Non-Dilutive Grant by the Israel Innovation Authority
TEL AVIV, Israel, Feb. 20, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT) (the “Company”) today announced that it has been awarded a non-dilutive grant of ...
February 20, 2019
HTG Molecular to Present Corporate Overview at the 8th Annual SVB Leerink Global Healthcare Conference
TUCSON, Ariz., Feb. 20, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, ...
February 20, 2019
RedHill Biopharma Strengthens Management Team with Appointment of Rick D. Scruggs as Chief Operating Officer, U.S. Operations
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 20, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
February 20, 2019
CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
NEWARK, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
February 20, 2019
Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), ...
February 20, 2019
Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme
NEW YORK and COLUMBUS, Ohio, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies ...
Page 41 of 169